MYC and prostate adenocarcinoma: These findings provide evidence that, in late-stage mCRPC, changes in mtDNAcn after drug treatment correlate with changes in MYC levels, further indicating that MYC may be a key regulator of mtDNAcn in prostatic adenocarcinomas.